Allen N M, Dunham G D, Sailstad J M, Findlay J W
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
DICP. 1991 Dec;25(12):1315-20. doi: 10.1177/106002809102501205.
Minimal pharmacokinetic data on digoxin immune Fab are currently available, especially in patients with impaired renal function. The serum concentration-time profiles of total digoxin, free digoxin, and digoxin immune Fab in four patients with moderate to severe renal impairment who received digoxin immune Fab are presented. The calculated elimination half-life of digoxin immune Fab was 25-73 hours. The calculated elimination half-life of total digoxin was 24-72 hours. Free digoxin concentrations rebounded to a peak of 1-2.9 ng/mL 44-97 hours after the administration of digoxin immune Fab. The areas under the curve for digoxin immune Fab were 213-1026 micrograms.h/mL, and total body clearances were 2.3-7.1 mL/min. The total digoxin concentrations peaked at 14-33 times the pre-Fab digoxin concentrations 5-30 hours after digoxin immune Fab administration. In comparing these data with data available from patients with normal renal function, the half-life of digoxin immune Fab and total digoxin was longer, the peak total digoxin concentration occurred later, the ratio of the peak total digoxin concentration to pre-Fab digoxin concentration was larger, and the rebound in free digoxin occurred later in patients with renal impairment. The Fab dose should not be reduced in patients with renal impairment; however, post-Fab monitoring should be extended to compensate for the prolonged half-life of Fab and later rebound of free digoxin.
目前关于地高辛免疫Fab的药代动力学数据极少,尤其是在肾功能受损的患者中。本文展示了4例中重度肾功能损害且接受了地高辛免疫Fab治疗的患者的总地高辛、游离地高辛和地高辛免疫Fab的血清浓度-时间曲线。计算得出地高辛免疫Fab的消除半衰期为25 - 73小时。总地高辛的计算消除半衰期为24 - 72小时。游离地高辛浓度在给予地高辛免疫Fab后44 - 97小时反弹至1 - 2.9 ng/mL的峰值。地高辛免疫Fab的曲线下面积为213 - 1026微克·小时/毫升,全身清除率为2.3 - 7.1毫升/分钟。总地高辛浓度在给予地高辛免疫Fab后5 - 30小时达到峰值,是给药前地高辛浓度的14 - 33倍。将这些数据与肾功能正常患者的现有数据相比,肾功能受损患者的地高辛免疫Fab和总地高辛半衰期更长,总地高辛浓度峰值出现得更晚,总地高辛浓度峰值与给药前地高辛浓度的比值更大,游离地高辛的反弹出现得更晚。肾功能受损患者不应降低Fab剂量;然而,Fab给药后监测应延长,以补偿Fab半衰期延长和游离地高辛后期反弹的影响。